Filing Flows › Pulmonx (LUNG) › Guidance & outlook
Pulmonx (LUNG) guidance and outlook
Pulmonx (LUNG) raised some and lowered other parts of its guidance on Oct 27, 2026: Revenue $90.0M–$92.0M for FY2026; Gross margin 77% for FY2026; Operating expenses $108M–$109M for FY2026. Pulmonx's 10-Q filed Nov 3, 2026 makes 43 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $90.0M–$92.0M | reaffirmed |
| Gross margin | FY2026 | 77% | raised |
| Operating expenses | FY2026 | $108M–$109M | lowered |
From the earnings release filed Oct 27, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- We also manufacture the AeriSeal System, which is a synthetic polymer foam designed to occlude, or close, collateral air channels in a target lung lobe and convert the target lung lobe to having little to no collateral ventilation (CV-).
- We intend to continue to make significant investments in our sales and marketing organization throughout the United States, Europe and Asia Pacific.
- We have made, and intend to continue to make, investments in research and development efforts to develop our next generation products and support our future regulatory submissions to increase our addressable market and to expand indications and new markets.
- Because of these and other factors, we expect to continue to incur net losses for the next several years and we expect to require substantial additional funding, which may include future equity and debt financings.
- We believe there are several important factors that have impacted and that we expect will continue to impact our business and results of operations.
- We have made, and intend to continue to make, significant investments in recruiting, training and retaining our direct sales force.
- This process requires significant education and training for our sales personnel to achieve the level of technical competency with our products that is expected by physicians and to gain experience building demand for our products.
- Upon completion of the training, our sales personnel typically require time in the field to grow their network of accounts and increase their productivity to the levels we expect.
- We have in the past and expect in the future to enter into different compensation arrangements with our sales professionals, which include minimum guaranteed commissions.
- This has impacted our compensation expenses in the past and we expect it will do so in the future.
- We intend to continue to promote awareness of our solution through training and educating physicians, pulmonary rehabilitation centers, key opinion leaders and various medical societies on the proven clinical benefits of Zephyr Valves.
- In addition, we intend to continue to publish additional clinical data in various industry and scientific
Pulmonx's latest quarter
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Pulmonx raise or lower its guidance?
Pulmonx (LUNG) raised some and lowered other parts of its guidance on Oct 27, 2026: Revenue $90.0M–$92.0M for FY2026; Gross margin 77% for FY2026; Operating expenses $108M–$109M for FY2026.
What does Pulmonx expect?
We also manufacture the AeriSeal System, which is a synthetic polymer foam designed to occlude, or close, collateral air channels in a target lung lobe and convert the target lung lobe to having little to no collateral ventilation (CV-). We intend to continue to make significant investments in our sales and marketing organization throughout the United States, Europe and Asia Pacific. We have made, and intend to continue to make, investments in research and development efforts to develop our next generation products and support our future regulatory submissions to increase our addressable marke
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.